Compare AKBA & ALIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | ALIT |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 826.0M |
| IPO Year | 2014 | N/A |
| Metric | AKBA | ALIT |
|---|---|---|
| Price | $1.42 | $1.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $5.92 | $4.70 |
| AVG Volume (30 Days) | 3.1M | ★ 10.8M |
| Earning Date | 03-12-2026 | 02-19-2026 |
| Dividend Yield | N/A | ★ 10.00% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $225,071,000.00 | ★ $2,289,000,000.00 |
| Revenue This Year | $52.41 | N/A |
| Revenue Next Year | $21.57 | $1.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.49 | N/A |
| 52 Week Low | $1.30 | $1.46 |
| 52 Week High | $4.08 | $7.66 |
| Indicator | AKBA | ALIT |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 43.39 |
| Support Level | $1.35 | $1.46 |
| Resistance Level | $1.44 | $1.69 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 42.50 | 52.17 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.